Purchase this article with an account.
M. Hennig, D. Bauer, S. Wasmuth, M. Busch, K. Wahlscheid, A. Heiligenhaus; Influence of Everolimus on the Course of the Experimental Autoimmune Uveitis (EAU). Invest. Ophthalmol. Vis. Sci. 2009;50(13):5918.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The experimental autoimmune uveitis (EAU) is a T-cell mediated disease model for the posterior uveitis. The aim of the current investigation was to analyze the influence of everolimus on the course of EAU.
The EAU susceptible mouse strain B10.RIII may develop EAU that is similar to the human posterior uveitis. The EAU was induced by (1) active immunization with IRBP-peptide or through (2) adoptive transfer of uveitogenic splenocytes. Mice were treated with everolimus at different periods of time. The eyes were analyzed histopathologically in order to determine the severity of EAU. The statistics were done with student's t-test.
The EAU score after active immunization (1) was 1.9±1 After treatment with everolimus between day -2 and day +21, the EAU score was improved to 0.3±0.6 (p<0.05). Treatment of EAU diseased mice results in a decreased proliferative response and DTH (delayed type of hypersensitivity).
The treatment of mice with the lymphocyte proliferation-inhibitor everolimus reduces the severity of EAU and the IRBP-specific T-cell response. The current investigation shows that everolimus is suitable for the therapy of T-cell mediated experimental uveitis.
This PDF is available to Subscribers Only